NASDAQ$ADVM
Adverum Biotechnologies Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Adverum completed enrollment of Phase 2 LUNA trial in wet AMD and reported second quarter 2023 financial results.
Adverum Biotechnologies announced the completion of enrollment in its Phase 2 LUNA trial evaluating Ixo-vec for wet AMD treatment and reported financial results for the second quarter ended June 30, 2023. The company's cash runway is projected into 2025.
- Completed enrollment in Phase 2 LUNA trial evaluating Ixo-vec for wet AMD.
- Combined OPTIC and LUNA trials will follow approximately 90 wet AMD subjects dosed with Ixo-vec out to five years.
- Anticipate aflibercept protein levels for percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023.
- Cash runway projected into 2025.
Headline financials
Revenue & EPS history
Adverum · Revenue · Quarterly
$0
Forward guidance
Adverum anticipates aflibercept protein levels for the percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023 and anticipates LUNA preliminary efficacy and safety data for percentage of cohort in Q4 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2023
+0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-2.5%
Avg return
30 days after
45%
17 / 38 earnings
Positive
+12.5%
Q3 2022
Best reaction
-15.5%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.9% | -1.2% | — | |
| Q2 2025 | +10.8% | +27.9% | +41.4% | |
| Q1 2025 | -1.0% | +21.0% | +19.5% | |
| Q4 2024 | -5.8% | -15.4% | -41.0% | |
| Q3 2024 | +4.2% | +8.4% | -18.5% | |
| Q2 2024 | +3.0% | +4.7% | +7.3% | |
| Q1 2024 | -5.2% | -9.3% | -25.1% | |
| Q4 2023 | -2.9% | -5.3% | -33.1% | |
| Q3 2023 | +1.8% | -3.4% | +0.0% | |
| Q2 2023 | +2.2% | -3.8% | -7.1% | |
| Q1 2023 | -4.6% | -4.1% | +89.3% | |
| Q4 2022 | -4.5% | -6.7% | +3.6% | |
| Q3 2022 | +12.5% | +3.2% | -9.6% | |
| Q2 2022 | -4.5% | -8.6% | -25.0% | |
| Q1 2022 | -14.1% | -13.5% | +2.7% | |
| Q4 2021 | -2.9% | -5.8% | -20.3% | |
| Q3 2021 | -5.6% | -1.3% | -24.9% | |
| Q2 2021 | +6.9% | — | — | |
| Q1 2021 | +3.3% | — | — | |
| Q4 2020 | -5.3% | — | — | |
| Q3 2020 | -7.8% | — | — | |
| Q2 2020 | -15.5% | — | — | |
| Q1 2020 | -1.9% | — | — | |
| Q4 2019 | +11.6% | — | — | |
| Q3 2019 | +8.9% | — | — | |
| Q2 2019 | -1.3% | — | — | |
| Q1 2019 | -3.7% | — | — | |
| Q4 2018 | +2.8% | — | — | |
| Q3 2018 | +1.9% | — | — | |
| Q2 2018 | +10.9% | — | — | |
| Q1 2018 | +3.6% | — | — | |
| Q4 2017 | -4.1% | — | — | |
| Q3 2017 | -6.3% | — | — | |
| Q2 2017 | -2.0% | — | — | |
| Q1 2017 | -1.8% | — | — | |
| Q3 2016 | +11.9% | — | — | |
| Q2 2016 | +2.3% | — | — | |
| Q3 2014 | +4.5% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro